Hre3327kcx | 2510782-14-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: Hre3327kcx
• 英文别名: (12Z,16R)-16-hydroxy-16-methyl-5-[4-(4-methylpiperazin-1-yl)anilino]-2,4,6,10,21-pentazatetracyclo[15.3.1.02,10.03,8]henicosa-1(20),3,5,7,12,17(21),18-heptaen-9-one
• CAS: 2510782-14-4
• 化学式: C₂₈H₃₂N₈O₂
• 分子量: 512.6
• InChiKey: KSZKLDQYICQTLL-WHQCRVIKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  38
• 可旋转键数：
  3
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• MACROCYCLIC COMPOUND SERVING AS WEE1 INHIBITOR AND APPLICATIONS THEREOF
  申请人：SHIJIAZHUANG SAGACITY NEW DRUG DEVELOPMENT CO., LTD.

  公开号：US20200325145A1

  公开（公告）日：2020-10-15

  Disclosed in the present invention are a macrocyclic compound serving as a Weel inhibitor, and applications thereof in the preparation of drugs for treating Weel-related diseases. The present invention specifically relates to a compound represented by formula (II), an isomer thereof, and a pharmaceutically acceptable salt thereof.

  本发明揭示了一种作为Weel抑制剂的大环化合物，以及在制备用于治疗与Weel相关疾病的药物中的应用。本发明具体涉及一种由式（II）表示的化合物，其异构体和其药用可接受的盐。
• CRYSTAL FORM OF WEE1 INHIBITOR COMPOUND AND USE THEREOF
  申请人：SHIJIAZHUANG SAGACITY NEW DRUG DEVELOPMENT CO., LTD

  公开号：US20220220120A1

  公开（公告）日：2022-07-14

  Disclosed is a crystal form of a compound of formula (I) and the use of the crystal form in the preparation of a drug for treating Wee1-related diseases.
• [EN] COMBINATIONS<br/>[FR] ASSOCIATIONS
  申请人：RECURIUM IP HOLDINGS LLC

  公开号：WO2021127041A1

  公开（公告）日：2021-06-24

  Disclosed herein are combinations of compounds for treating a disease or condition, such as cancer. A combination of compounds for treating a disease or condition can include a Bcl-2 inhibitor and a WEE1 inhibitor, along with pharmaceutically acceptable salts of any of the foregoing.
• [EN] WEE1 INHIBITORS AND METHODS FOR TREATING CANCER<br/>[FR] INHIBITEURS DE WEE1 ET MÉTHODES DE TRAITEMENT DU CANCER
  申请人：[en]RECURIUM IP HOLDINGS, LLC

  公开号：WO2022136916A1

  公开（公告）日：2022-06-30

  Disclosed herein is a method of determining subject sensitivity to a WEE1 inhibitor, comprising obtaining or having obtained a biological sample from the subject, and performing or having performed at least one assay on the biological sample to determine if the subject has an altered DNA repair function of NBN, MRE11, RAD50 or MRE11-RAD50-NBN (MRN) protein complex. Also disclosed are methods of treating cancer with WEE1 inhibitors, and modifying the effective concentration based upon the sequence variation and function of NBN, MRE11, RAD50 or MRE11-RAD50-NBN (MRN) protein complex.